Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 1c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Jabil (JBL) Tops Q3 EPS by 8c, Offers Guidance
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold